Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Cash from Operations: 2019-2024

Historic Cash from Operations for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to -$160.9 million.

  • Keros Therapeutics' Cash from Operations rose 110.65% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.8 million, marking a year-over-year increase of 163.28%. This contributed to the annual value of -$160.9 million for FY2024, which is 29.20% down from last year.
  • According to the latest figures from FY2024, Keros Therapeutics' Cash from Operations is -$160.9 million, which was down 29.20% from -$124.5 million recorded in FY2023.
  • In the past 5 years, Keros Therapeutics' Cash from Operations ranged from a high of -$36.9 million in FY2020 and a low of -$160.9 million during FY2024.
  • In the last 3 years, Keros Therapeutics' Cash from Operations had a median value of -$124.5 million in 2023 and averaged -$118.5 million.
  • Data for Keros Therapeutics' Cash from Operations shows a maximum YoY slumped of 130.62% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Keros Therapeutics' Cash from Operations stood at -$36.9 million in 2020, then crashed by 68.45% to -$62.1 million in 2021, then decreased by 12.73% to -$70.1 million in 2022, then slumped by 77.71% to -$124.5 million in 2023, then fell by 29.20% to -$160.9 million in 2024.